Excipient-mediated supersaturation stabilization in human intestinal fluids

Molecular Pharmaceutics

Volumn 8, Issue 2, 2011, Pages 564-570

  Bevernage, Jan ^a   Forier, Thomas ^a   Brouwers, Joachim ^a   Tack, Jan ^b   Annaert, Pieter ^a   Augustijns, Patrick ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

biorelevant; precipitation inhibition; solubility; supersaturation

Indexed keywords

BUFFER; DANAZOL; ETRAVIRINE; EXCIPIENT; FENOFIBRATE; HYDROXYPROPYLMETHYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE ACETATE SUCCINATE; HYDROXYPROPYLMETHYLCELLULOSE E4M; HYDROXYPROPYLMETHYLCELLULOSE E5; HYDROXYPROPYLMETHYLCELLULOSE E50; HYDROXYPROPYLMETHYLCELLULOSE PHTHALATE; LOVIRIDE; RITONAVIR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DRUG ELIMINATION; DRUG FORMULATION; DRUG SOLUBILITY; FEMALE; HUMAN; INTESTINE FLUID; MALE; NORMAL HUMAN; NUTRITIONAL STATUS; PHYSICOCHEMICAL MODEL; PRECIPITATION; PRIORITY JOURNAL; SIMULATION; SOLVENT EFFECT;

ACETAMIDES; ACETOPHENONES; ADULT; BODY FLUIDS; DANAZOL; EXCIPIENTS; FEMALE; FENOFIBRATE; HUMANS; INTESTINES; MALE; PHARMACEUTICAL PREPARATIONS; POLYMERS; PYRIDAZINES; RITONAVIR; SOLUBILITY; YOUNG ADULT;

EID: 79953806124     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100377m     Document Type: Article

References (20)

1. Connors, R. D.; Elder, E. J. Using a Portfolio of Particle Growth Technologies to Enable Delivery of Drugs With Poor Water Solubility. Drug Delivery Technol. 2004, 4, 78-83.
2. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44, 235-249.
3. Brouwers, J.; Brewster, M. E.; Augustijns, P. Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability? J. Pharm. Sci. 2009, 98, 2549-2572.
4. Vandecruys, R.; Peeters, J.; Verreck, G.; Brewster, M. E. Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design. Int. J. Pharm. 2007, 342, 168-175.
5. Brewster, M. E.; Vandecruys, R.; Verreck, G.; Peeters, J. Supersaturating drug delivery systems: effect of hydrophilic cyclodextrins and other excipients on the formation and stabilization of supersaturated drug solutions. Pharmazie 2008, 63, 217-220. (Pubitemid 351449932)
6. Curatolo, W.; Nightingale, J. A.; Herbig, S. M. Utility of hydroxypropylmethylcellulose acetate succinate (HPMCAS) for initiation and maintenance of drug supersaturation in the GI milieu. Pharm. Res. 2009, 26, 1419-1431.
7. Raghavan, S. L.; Trividic, A.; Davis, A. F.;Hadgraft, J. Crystallization of hydrocortisone acetate: influence of polymers. Int. J. Pharm. 2001, 212, 213-221.
8. Miller, D. A.; DiNunzio, J. C.; Yang, W.; McGinity, J. W.; Williams, R. O. Enhanced in vivo absorption of itraconazole via stabilization of supersaturation following acidic-to-neutral pH transition. Drug Dev. Ind. Pharm. 2008, 34, 890-902.
9. Gao, P.; Akrami, A.; Alvarez, F.; Hu, J.; Li, L.; Ma, C.; Surapaneni, S. Characterization and optimization of AMG 517 supersaturatable selfemulsifying drug delivery system (S-SEDDS) for improved oral absorption. J. Pharm. Sci. 2009, 98, 516-528.
10. Dai, W.; Dong, L. C.; Li, S.; Deng, Z. Combination of Pluronic/Vitamin E TPGS as a potential inhibitor of drug precipitation. Int. J. Pharm. 2008, 355, 31-37.
11. Guzmán, H. R.; Tawa, M.; Zhang, Z.; Ratanabanangkoon, P.; Shaw, P.; Gardner, C. R.; Chen, H.; Moreau, J.; Almarsson, O.; Remenar, J. F. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J. Pharm. Sci. 2007, 96, 2686-2702.
12. Dias, M. M. R.; Raghavan, S. L.; Pellett, M. A.; Hadgraft, J. The effect of beta-cyclodextrins on the permeation of diclofenac from supersaturated solutions. Int. J. Pharm. 2003, 263, 173-181.
13. Carlert, S.; Pålsson, A.; Hanisch, G.; von Corswant, C.; Nilsson, C.; Lindfors, L.; Lennernäs, H.; Abrahamsson, B. Predicting intestinal precipitation - a case example for a basic BCS class II drug. Pharm. Res. 2010, 27, 2119-2130.
14. Bevernage, J.; Brouwers, J.; Clarysse, S.; Vertzoni, M.; Tack, J.; Annaert, P.; Augustijns, P. Drug supersaturation in simulated and human intestinal fluids representing different nutritional states. J. Pharm. Sci. 2010, 99, 4525-4534.
15. Warren, D. B.; Benameur, H.; Porter, C. J. H.; Pouton, C. W. Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: A mechanistic basis for utility. J. Drug Targeting 2010, 18, 704-731.
16. Clarysse, S.; Tack, J.; Lammert, F.; Duchateau, G.; Reppas, C.; Augustijns, P. Postprandial evolution in composition and characteristics of human duodenal fluids in different nutritional states. J. Pharm. Sci. 2009, 98, 1177-1192.
17. Vertzoni, M.; Fotaki, N.; Kostewicz, E.; Stippler, E.; Leuner, C.; Nicolaides, E.; Dressman, J.; Reppas, C. Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects. J. Pharm. Pharmacol. 2004, 56, 453-462.
18. Clarysse, S.; Psachoulias, D.; Brouwers, J.; Tack, J.; Annaert, P.; Duchateau, G.; Reppas, C.; Augustijns, P. Postprandial changes in solubilizing capacity of human intestinal fluids for BCS class II drugs. Pharm. Res. 2009, 26, 1456-1466.
19. Annaert, P.; Brouwers, J.; Bijnens, A.; Lammert, F.; Tack, J.; Augustijns, P. Ex vivo permeability experiments in excised rat intestinal tissue and in vitro solubility measurements in aspirated human intestinal fluids support age-dependent oral drug absorption. Eur. J. Pharm. Sci. 2010, 39, 15-22.
20. Bauer, J.; Spanton, S.; Henry, R.; Quick, J.; Dziki, W.; Porter, W.; Morris, J. Ritonavir: an extraordinary example of conformational polymorphism. Pharm. Res. 2001, 18, 859-866.